Dental Bone Graft Substitute Market Size, Share, & Trends Analysis | Global | 2026-2032 | Includes: Allografts, Xenografts, and Synthetic Grafts

Global Dental Bone Graft Substitute Market Report to 2032

The global dental bone graft substitute market was valued at $1.19 billion in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 7.3%, reaching nearly $1.95 billion by 2032.

This comprehensive report covers the global market for dental bone graft substitutes (DBGSs), including allograft, xenograft and synthetic DBGS products.

The analysis includes unit sales, average selling prices (ASPs), market size, growth trends, market drivers and limiters, market forecasts through 2032, and historical data back to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Growth is supported by the global expansion of dental implant procedures, rising clinician experience with grafting and increasing acceptance of biologically derived graft materials. However, cost barriers, improving dental health and regional differences in biologic material acceptance continue to shape market performance.

Market Overview

The global dental bone graft substitute market includes materials used to repair bone defects, prepare implant sites and support bone regeneration in dental procedures. DBGS products are most commonly used in implant-related procedures, including socket preservation, sinus augmentation and ridge augmentation.

The market is segmented into allografts, xenografts and synthetic bone graft substitutes. Allografts are derived from human donor tissue, xenografts are derived from animal sources such as bovine or porcine materials, and synthetic grafts are manufactured from non-biologic materials.

In 2025, xenografts represented the largest share of total market value. Xenograft products are widely used in many regions because of their availability, consistent quality and established clinical performance. Allografts represented the second-largest segment, with particularly strong adoption in North America.

Synthetic DBGS products represented the smallest material segment, but they are expected to gain share over the forecast period. Their growth is supported by lower disease transmission concerns, scalable production and use in regions where human- or animal-derived grafts face regulatory, cultural or supply limitations.

Market Drivers

Increased consumer awareness is a major driver of the dental bone graft substitute market. As dental implants become more popular, demand for grafting materials rises because many implant patients require site preparation before implant placement. This connects DBGS growth directly to the broader dental implant market.

Many dental implant companies now offer regenerative materials alongside implant systems. This has increased marketing activity, clinician education and dedicated sales efforts around bone graft substitutes. As companies promote grafting as part of a complete implant workflow, more clinicians and patients become aware of the role DBGS products play in successful implant treatment.

Rising clinician experience is also supporting market growth. Dental professionals who perform bone grafting procedures are becoming more comfortable with available materials and techniques. This has led to greater use of more sophisticated products, including hybrid cortical-cancellous allografts and DBM putties with mineralized bone chips. As clinicians gain confidence, premium-priced products are becoming more common in advanced regenerative procedures.

Market Limiters

Improving dental health is a long-term limiter for the dental bone graft substitute market. In many regions, better awareness of oral health and more frequent dental checkups are reducing edentulism. As aging populations retain better dentition than previous generations, the pool of patients requiring extensive grafting may shrink in certain markets.

Large bone grafting procedures also limit adoption because they can be expensive. Procedures such as ridge augmentation may require 5 cc to 10 cc of graft material. In some cases, the grafting portion of treatment can cost more than the dental implant itself, creating a financial barrier for patients.

Regional acceptance of biologically derived grafts can also limit adoption. Advances in processing, sterilization and traceability have improved confidence in allografts and xenografts, but adoption still varies by regulation, cultural preference, donor tissue availability and clinician comfort. These factors can limit growth in some countries while supporting alternative use of synthetic grafts.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
• Qualitative coverage: Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Data types included: Unit sales, average selling prices, market size and growth trends, market drivers and limiters, market forecasts through 2032, historical data, recent mergers and acquisitions, company profiles and product portfolios.
• Method note: Market revenue is modeled using unit sales and average selling prices, with segmentation by graft material and application used to assess demand across allograft, xenograft and synthetic DBGS products.

The report is designed to help readers evaluate how dental implant growth, material selection, biologic graft acceptance, regional adoption and patient affordability are shaping the global dental bone graft substitute market.

Markets Covered and Segmentation

Dental Bone Graft Substitute Market

• Type: Allograft, xenograft and synthetic.
• Application: Socket preservation, sinus augmentation, ridge augmentation and periodontal procedure.

Application segmentation is analyzed at a unit level only.

Allografts include human-derived graft materials used in regenerative dental procedures. These products are especially important in North America, where tissue banking infrastructure and clinician acceptance are well established.

Xenografts include animal-derived graft materials, most commonly bovine or porcine sources. This segment represents the largest share of global DBGS market value.

Synthetic DBGS products are manufactured graft substitutes that do not originate from human or animal sources. These products are relevant in markets where biologic grafts face regulatory, cultural or supply-related limits.

Each segment is analyzed through relevant quantitative measures, including market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Competitive Analysis

In 2025, Geistlich remained the leading competitor in the global dental bone graft substitute market. The company's leadership is driven primarily by its strong position in the xenograft segment, which accounts for a substantial share of DBGS usage outside North America. Its Bio-Oss(R) bovine xenograft portfolio is widely regarded as a clinical reference standard, supported by long-term clinical evidence and global adoption.

Geistlich has continued to refine and expand its Bio-Oss(R) offerings, including smaller-volume formats designed for narrow defects and minor augmentation procedures. This improves procedural flexibility for clinicians and supports continued use across different grafting indications. The company's broader focus on biologically driven regeneration also strengthens its position across the wider dental biomaterials market.

Henry Schein was the second-leading competitor in the DBGS market in 2025 through BioHorizons. BioHorizons offers MinerOss(R), Grafton(R) DBM and LADDEC(R) graft materials, covering several regenerative indications. Through BioHorizons and ACE Southern, Henry Schein participates across allograft, xenograft and synthetic substitute categories.

ZimVie was the third-leading competitor in the global DBGS market in 2025. Its portfolio includes Puros(R) allografts, RegenerOss(R) graft materials, Endobon(R) xenografts and IngeniOs(R) synthetic graft substitutes. Following its 2025 acquisition by ARCHIMED, ZimVie is positioned for continued investment in dental implants and regenerative biomaterials.

Technology and Practice Trends

Biologically derived graft materials remain an important growth area. Allografts and xenografts continue to gain acceptance as processing, sterilization and traceability standards improve.

Xenografts remain a major global material category. Their availability, consistent quality and established clinical performance support wide adoption, especially outside North America.

Allografts continue to perform strongly in North America. The region benefits from mature tissue banking infrastructure, standardized donor screening and strong regulatory oversight.

Synthetic grafts are expected to gain share in certain regions. They offer scalable supply, no human or animal origin and no disease transmission risk, which can make them attractive in markets with regulatory, cultural or ethical concerns around biologic materials.

Premium graft materials are becoming more common as clinicians gain experience. Hybrid cortical-cancellous mixtures, DBM putties and specialized formats are being used to support more complex regenerative cases.

Product format innovation is also important. Smaller-volume graft formats, moldable materials and easier-handling products give clinicians more flexibility when treating narrow defects, socket preservation cases and other routine augmentation needs.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

How large is the global dental bone graft substitute market, and how is it expected to grow through 2032?

How are allograft, xenograft and synthetic DBGS products performing across global markets?

How are unit sales, average selling prices and market values changing over time?

Why does dental implant growth continue to support demand for bone graft substitutes?

How are biologically derived graft materials gaining acceptance across different regions?

Why do xenografts remain the largest DBGS material category globally?

How are clinician experience and premium graft materials affecting market value?

What role do cost barriers, improving dental health and large grafting procedures play in limiting adoption?

Which companies lead the DBGS market, and how are Geistlich, Henry Schein and ZimVie positioned?

The Global Dental Bone Graft Substitute Market Report from iData Research answers these questions with detailed market sizing, ASP trends, forecasts and competitive share insights. Use it to evaluate demand, benchmark leading competitors, understand material trends and plan for growth across the global dental bone graft substitute market.